Use of Minocicline in Patients With Stroke

Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01556802

Enrollment

134

Registered

2012-03-16

Start date

2011-10-31

Completion date

2013-01-31

Last updated

2012-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Ischemia, Paralysis, Stroke

Keywords

stroke, sequelaes, minocicline

Brief summary

The investigators will evaluate the National Institute of Health Stroke Scale/Score (NIHSS)in patients with stroke, and then give Minocycline 100mg po every 12 hours or placebo for five days, then perform periodic evaluations to determine the status and degree of neurological sequelae developed.

Interventions

DRUGMinocicline

Minocicline 100mg oral twice a day for 5 days

DRUGPlacebo

Pills with vegetable fibers one pill oral twice a day for five days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* NIHSS scale greater than 5 * Onset of symptoms less than 24 hours * normal Cranial Tomography(CT) * CT evidence of cerebral ischemia * Acceptance of study entry

Exclusion criteria

* Hemorrhagic cerebrovascular disease * Other neurological diseases * Concomitant structural damage * History of neurosurgery * Known allergy to tetracyclines * Concomitant infectious diseases requiring antibiotic treatment. * History of Stroke * Women pregnant or breast-feeding

Design outcomes

Primary

Measure	Time frame	Description
To determine the efficacy of minocycline in reducing neurological sequelae in patients with stroke	one year	The researchers evaluated the neurological condition of paralysis, aphasia,and level of consciousness by NIHSS score for each patient with stroke and proceeded to give minocycline or placebo. Then, the assessment was repeated after five and thirty days post treatment to determine whether their neurological sequelae had diminushed.

Secondary

Measure	Time frame
Identify the side effects of the intervention administered during the treatment time and 30 days later.	one year

Countries

Colombia

Contacts

Primary ContactNataly Bedoya, md

nata0916@hotmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026